Zacks Investment Research Upgrades ThermoGenesis (NASDAQ:THMO) to “Hold”

ThermoGenesis (NASDAQ:THMO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “ThermoGenesis Holdings Inc. develops, commercializes and markets automated technologies for CAR-T and other cell-based therapies. The company markets solutions for automated clinical biobanking, point-of-care applications and automation for immuno-oncology. ThermoGenesis Holdings Inc., formerly known as Cesca Therapeutics Inc., is based in Rancho Cordova, California. “

Shares of NASDAQ THMO opened at $1.83 on Thursday. ThermoGenesis has a 12 month low of $1.73 and a 12 month high of $4.45. The company has a 50-day simple moving average of $2.20 and a 200-day simple moving average of $2.44. The company has a market cap of $21.80 million, a PE ratio of -1.52 and a beta of 3.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.35 and a quick ratio of 0.86.

ThermoGenesis (NASDAQ:THMO) last announced its quarterly earnings results on Thursday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.20). ThermoGenesis had a negative net margin of 152.92% and a negative return on equity of 178.57%. The business had revenue of $2.20 million for the quarter, compared to analyst estimates of $1.99 million. On average, analysts anticipate that ThermoGenesis will post -0.7 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in THMO. Vanguard Group Inc. grew its position in shares of ThermoGenesis by 276.4% during the second quarter. Vanguard Group Inc. now owns 259,610 shares of the company’s stock worth $688,000 after acquiring an additional 190,645 shares during the last quarter. Citadel Advisors LLC acquired a new stake in ThermoGenesis in the 1st quarter valued at about $244,000. Goldman Sachs Group Inc. lifted its stake in ThermoGenesis by 106.9% during the first quarter. Goldman Sachs Group Inc. now owns 49,769 shares of the company’s stock valued at $134,000 after buying an additional 25,711 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in ThermoGenesis during the second quarter valued at about $59,000. Finally, State Street Corp purchased a new stake in ThermoGenesis during the second quarter valued at about $45,000. Hedge funds and other institutional investors own 3.80% of the company’s stock.

About ThermoGenesis

ThermoGenesis Holdings, Inc engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It operates through the Device and Clinical Development segment. The Device segment includes the development and commercialization of automated technologies for cell-based therapeutics and bioprocessing.

Featured Story: What are economic reports?

Get a free copy of the Zacks research report on ThermoGenesis (THMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with MarketBeat.com's FREE daily email newsletter.